Pliant Therapeutics (PLRX) EPS (Weighted Average and Diluted) (2019 - 2026)
Pliant Therapeutics (PLRX) reported EPS (Weighted Average and Diluted) of -$0.32 for Q1 2026, up 65.22% year-over-year from -$0.19 in Q1 2025, and up 15.79% quarter-over-quarter from -$0.38 in Q4 2025.
Pliant Therapeutics (PLRX) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.32 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.32, up 65.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.84 (up 48.89% YoY), and the FY2025 annual result was -$2.43, up 29.97% from the prior year.
- EPS (Weighted Average and Diluted) grew to -$0.32 in Q1 2026 per PLRX's latest filing, from -$0.38 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.32 in Q1 2026 and troughed at -$0.95 in Q3 2024.
- A 5-year average of -$0.7 and a median of -$0.71 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2026: EPS (Weighted Average and Diluted) sank 35.71% in 2024, then surged 65.22% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.72 in 2022, then increased by 4.17% to -$0.69 in 2023, then declined by 17.39% to -$0.81 in 2024, then jumped by 53.09% to -$0.38 in 2025, then grew by 15.79% to -$0.32 in 2026.
- Business Quant data shows PLRX's EPS (Weighted Average and Diluted) at -$0.32 in Q1 2026, -$0.38 in Q4 2025, and -$0.43 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - | -0.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.32 |
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.43 |
| Jun 30, 2025 | -0.71 |
| Mar 31, 2025 | -0.92 |
| Dec 31, 2024 | -0.81 |
| Sep 30, 2024 | -0.95 |
| Jun 30, 2024 | -0.92 |
| Mar 31, 2024 | -0.78 |
| Dec 31, 2023 | -0.69 |
| Sep 30, 2023 | -0.70 |
| Jun 30, 2023 | -0.70 |
| Mar 31, 2023 | -0.67 |
| Dec 31, 2022 | -0.72 |
| Sep 30, 2022 | -0.65 |
| Jun 30, 2022 | -0.82 |
| Mar 31, 2022 | -0.78 |
| Dec 31, 2021 | -0.68 |
| Sep 30, 2021 | -0.75 |
| Jun 30, 2021 | -0.64 |